Trial · NCT04588792
Furosemide as Supportive Therapy for COVID-19 Respiratory Failure
NCT04588792, Phase 2, Phase 3, Terminated, Dr. John Muscedere
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Furosemide as Supportive Therapy for COVID-19 Respiratory Failure. Trials, record NCT04588792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04588792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Furosemide as Supportive Therapy for COVID-19 Respiratory Failure
- NCT number
- NCT04588792
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- Dr. John Muscedere
- Conditions
- Covid19, Respiratory Failure
- Interventions
- Nebulized Furosemide, Nebulized Saline
- First posted
- 2020-10-19
- Last updated
- 2023-12-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in pulmonary gas exchange | Study Day 6 | Improvement in oxygenation as determined by a standardized PaO2/FiO2 ratio |
| Primary | Requirement for mechanical ventilation | Baseline to day 28 | Number of ventilator-free days in the first 28 days after enrollment |
| Secondary | Mortality | Day 60 post enrollment | All Cause |
| Secondary | Requirement for supplemental oxygen | To day 28 post enrollment | Number of days of alive and not requiring supplemental oxygen |
| Secondary | Duration of ICU Stay | Up to 60 days post enrollment | Duration of ICU Stay |
| Secondary | Length of hospitalization | Up to 60 days post enrollment | Length of hospitalization |
| Secondary | Adverse events | Up to 60 days post enrollment | Incidence of serious adverse events: incorporated as trial outcomes, defined a priori, in accordance with guidelines for academic ICU drug trials |
| Secondary | Inhalation adverse events | Up to day 28 | Adverse events during the nebulization of furosemide |
| Other | Serum levels of furosemide | Up to day 28 | Serum levels of furosemide every 7 days until the completion of therapy |
| Other | Electrolyte abnormalities | Up to day 28 | Altered electrolytes on routine testing (frequency of hypokalemia (\< 3.0 meq/L), hypernatremia (\> 150 meq/L) or increased bicarbonate levels (\>30 meq/L) during the ICU stay |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04588792
GET https://conductscience.org/api/trials/v1/NCT04588792/registered